Eluxadoline Intermediate Synthesis via Crystallization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing process for synthesizing Eluxadoline intermediate compound II requires purification by column chromatography, reducing yield and is not suitable for large-scale production.
Innovation Solution
A novel process involving steps such as treating L-alanine with an amino protecting group, reacting with phenacyl chloride, and converting to an oxalate salt, which allows for high yield and purity without chromatographic purification, and is adaptable for industrial scaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If column chromatography is used for purification of compound II, then purity is improved, but yield is reduced and the process becomes unsuitable for large-scale synthesis
Solution Approach 1:
The invention changes the purification approach from column chromatography to crystallization by forming diastereomeric salts with chiral acids. This parameter change in purification methodology eliminates the need for chromatographic separation, thereby improving yield while maintaining high purity of the final product
Solution Approach 2:
The invention introduces chiral acids (such as camphorsulfonic acid, mandelic acid, or tartaric acid) as intermediary agents that form diastereomeric salts with the amino compound. These intermediaries enable selective crystallization and separation of enantiomers without requiring column chromatography, thus resolving the contradiction between purity and yield
2Manufacturing precision
If column chromatography is used for purification of compound II, then purity is improved, but the process becomes unsuitable for large-scale synthesis
Solution Approach 1:
The invention transitions from chromatographic purification to crystallization-based purification, changing the fundamental parameter of the purification process. Crystallization is inherently more scalable and easier to implement in large-scale manufacturing compared to column chromatography, while still achieving high purity through selective crystal formation of diastereomeric salts
Solution Approach 2:
Chiral acids are introduced as intermediary substances that form diastereomeric salts with the amino compound. These intermediaries enable purification through crystallization, a technique that is well-suited for large-scale manufacturing, thereby improving ease of manufacture and scalability while maintaining high purity
3Quantity of substance
If conventional synthesis process is used, then compound II can be prepared, but costly chromatographic purification is required
Solution Approach 1:
The invention changes the purification parameter from expensive column chromatography to cost-effective crystallization. By forming diastereomeric salts with chiral acids and utilizing their different solubility properties, the process achieves purification through simple filtration and washing, dramatically reducing manufacturing costs while maintaining compound production
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves high purity and yield of the compound, facilitating industrial scalability and eliminating the need for costly chromatographic purification.
Implementation Method 1
Treating L-alanine with an amino protecting group to obtain an amino protected L-alanine
Implementation Method 2
Reacting the amino protected L-alanine with phenacyl chloride to obtain compound of formula (A-2a)
Implementation Method 3
Treating compound of formula (A-2a) with ammonium acetate to form an amino protected (S)-1-(4-phenyl-1-H-imidazol-2-yl)-ethanamine
Implementation Method 4
Treating the amino protected (S)-1-(4-phenyl-1-H-imidazol-2-yl)-ethanamine with a suitable acid to obtain an amino protected (S)-1-(4-phenyl-1-H-imidazol-2-yl)-ethanamine acid salt of formula (A-4a)
Implementation Method 5
converting the amino protected (S)-1-(4-phenyl-1-H-imidazol-2-yl)-ethanamine acid salt of formula (A-4a) to amino protected (S)-1-(4-phenyl-1-H-imidazol-2-yl)-ethanamine by treatment with a base
Data Source
AI summary
The invention relates to an improved process for preparing [(S)-1-(4-phenyl-1-H-imidazol-2-yl)-ethyl]-amine. The process involves formation of the novel intermediate crystalline compound [(S)-1-(4-phenyl-1-H-imidazol-2-yl)-ethyl]-carbamic acid tert-butyl ester oxalate.